Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
. o S7 _5 z$ B- w* {) K. D" V. _7 o. p P7 t: p5 z
: X3 O3 k U5 ~2 Z! c2 N3 \
Sub-category:
: r: n1 q0 G! a3 h* I1 \Molecular Targets
. g3 D/ O$ ]$ T8 t3 P* a5 z' @8 x* _" d* p+ F+ w
5 i8 f3 t f7 P6 V
Category:
' `2 U. q3 f: Y5 R8 DTumor Biology ! k$ } R- U* w$ U0 l
2 ~+ a/ U5 |# u# B0 Y. ?* u9 l" y; [. l# x
Meeting:- ]: F- d: @; @$ @3 Y4 y; G# [
2011 ASCO Annual Meeting
, A$ E J) F" n) G6 Q+ b/ i6 g; X$ \ u, F9 W) a6 U0 K
1 u' ?0 H4 a: F) b1 v3 t" i* `; {Session Type and Session Title:
+ h/ I* _. W. Y( E$ {$ [Poster Discussion Session, Tumor Biology
0 m& |/ j: b, F+ r0 Y$ f0 G6 E8 `( f! k3 ^4 K3 L6 z, o
- [6 I6 @; M9 d4 C
Abstract No:
: Z0 O" r0 K, z$ q1 w10517 . \; q' [( H& W% K5 D0 u
4 ^+ v7 Y6 }- l" F- v$ B1 T. ]/ {
5 r2 N \- h1 X* T4 q0 c9 ?Citation:
' ]! D# K( T+ u; {J Clin Oncol 29: 2011 (suppl; abstr 10517) 2 C. B8 Y9 n* B# ~, a
: v4 y1 N7 I# W7 J! g9 r# D. N* r( ?9 @. t/ x) O
Author(s):+ w" n! }1 ]8 q
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China , S) o. _- W7 x' U4 x9 s+ t/ c/ `" C( m
5 F. Z7 w* ^$ T3 G% Y
* {! l. ~( @% X
7 O: ~3 O) Q5 P: [( F' qAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.7 L: G% Y4 A; F; [' B/ a# w
' q" o; M- v5 y9 H0 ~! FAbstract Disclosures0 G9 s$ t/ a0 A
- N( O" @5 {/ Q) Z' O0 M/ sAbstract:# k, c) E! t% J0 h' v
" W% p0 y: i* o: h: ]: F8 Z. d) q
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
6 F4 l) M5 D: q* S2 g: n' n
# a" t8 v/ U; z) P$ s6 B" y
( s; d. k) A$ L- b# F |